Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
NCT ID: NCT00056966
Last Updated: 2012-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
24 participants
INTERVENTIONAL
2002-11-30
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Usually these patients are given high doses of chemotherapy before receiving a stem cell transplant to keep their immune system from rejecting the donor stem cells and to kill any diseased cells that remain in the body. However, this group of patients have a high risk of developing possibly life-threatening treatment-related side effects such as infections, damage to vital organs such as lungs, liver, kidney and heart, as well as graft versus host disease (GVHD).
Instead of the high dose chemotherapy and radiotherapy usually given before a transplant, this research study uses a new pre-transplant combination of three drugs, Fludarabine, Anti-CD45 and CAMPATH-1H with low dose radiotherapy. Fludarabine is a chemotherapy drug while Anti-CD45 and CAMPATH-1H are antibodies against certain types of blood cells, including those which are causing this disease. CAMPATH-1H is particularly important because it stays active in the body for a long time after it is given, which means it may work longer to prevent GVHD symptoms. Anti-CD45 may help in eradicating residual malignant cells. All these agents also help in preventing rejection of donor stem cells. This study is designed to give a less intense chemotherapy and radiotherapy, so that the life-threatening toxicities of conventional high dose chemotherapy and radiotherapy regimen can be reduced, while maintaining the ability to cure cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Day - 8: CAMPATH-1H and Fludarabine
* Day - 7: CAMPATH-1H and Fludarabine
* Day - 6: CAMPATH-1H and Fludarabine
* Day - 5: Anti-CD45 and Fludarabine
* Day - 4: Anti-CD45
* Day - 3: Anti-CD45
* Day - 2: Anti-CD45
* Day - 1: TBI
* Day 0: Stem Cell Infusion (transplant)
To help prevent the body from developing GVHD, patients will also receive the drug FK506, starting two days before the transplant and continuing for at least one month.
Both the CAMPATH-1H and the Anti-CD45 can cause allergic reactions so patients will be given drugs to help prevent those reactions before receiving daily doses.
To see how CAMPATH-1H works in patients with hematologic malignancies, some patients will be asked to participate in pharmacokinetic studies. For this, approximately 13 blood samples will be taken from the central line scheduled before each infusion on Day -8 to Day -6, daily thereafter until Day 0, and then approximately once per week on days 7, 14, 21 and 28 post transplant. No more than 5 teaspoonfuls total will be drawn.
To see how Anti-CD45 works in patients with hematologic malignancies some patients will be asked to participate in pharmacokinetic studies. Approximately 22 blood samples will be taken from the central line scheduled before, during and after each infusion and after the end of the last infusion of Anti-CD45. No more than 10 teaspoonfuls total will be drawn over the course of the four anti-CD45 infusions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
recipients of HLA matched sibling transplants
ANTI-CD45
400ug/kg Day-5 through Day-2
CAMPATH-1H
Day -8 through Day -6 Dosed per Institutional SOP
FK506
Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
Fludarabine
Day-8 through Day-5 30 mg/m2
Total Body Irradiation
Day-1 single dose 450 cGy
Stem cell infusion
Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count \>2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count \>2 x 108/kg) will be substituted.
2
recipients of unrelated or mismatched family donor transplants
ANTI-CD45
400ug/kg Day-5 through Day-2
CAMPATH-1H
Day -8 through Day -6 Dosed per Institutional SOP
FK506
Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
Fludarabine
Day-8 through Day-5 30 mg/m2
Total Body Irradiation
Day-1 single dose 450 cGy
Stem cell infusion
Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count \>2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count \>2 x 108/kg) will be substituted.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ANTI-CD45
400ug/kg Day-5 through Day-2
CAMPATH-1H
Day -8 through Day -6 Dosed per Institutional SOP
FK506
Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
Fludarabine
Day-8 through Day-5 30 mg/m2
Total Body Irradiation
Day-1 single dose 450 cGy
Stem cell infusion
Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count \>2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count \>2 x 108/kg) will be substituted.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Acute myeloid leukemia either a) Primary refractory, or b) Beyond first complete remission(CR1), or c) In CR1 with high risk of relapse
Acute lymphoblastic leukemia either a) Primary refractory, or b) Beyond first complete remission(CR1), or c) In CR1 with high risk of relapse
Chronic myeloid leukemia, either a) Accelerated phase, or b) Blast crisis, or c) Chronic phase and not achieving major cytogenetic response despite standard therapy
Chronic lymphocytic leukemia, either a) Primary refractory, or b) Beyond first complete remission(CR1),
Non Hodgkin's lymphoma, either a) Primary refractory, or b) Beyond first complete remission(CR1)
Hodgkin's disease, either a) Primary refractory, or b) Beyond first complete remission(CR1),
Myelodysplastic syndrome with IPSS score \> 0. (Appendix A)
Myeloproliferative disorders (with the exclusion of chronic myeloid leukemia) a) Primary Myelofibrosis with Lile score of 1 or 2 (Appendix B) b) Polycythemia Vera or Essential Thrombocythemia transformed to AML or Myelofibrosis and PV "spent phase"
Multiple Myeloma with stage II or III disease
Severe aplastic anemia
2. Conditions that increase Treatment Related Mortality (need one or more to be eligible):
Greater or equal to 35 years of age;
Ejection Fraction of less than 50%;
DLCO less than 50% or FEV1/FVC \< 80% of predicted value;
Diabetes Mellitus;
Renal insufficiency (serum creatinine abnormal);
Hepatic dysfunction-transaminases, or alkaline phosphatase, or bilirubin twice the upper limit of normal;
Prior recent history of systemic fungal infection;
Multiple prior treatment regimens (equal to or more than 3);
Significant Grade III or IV neurologic, cardiac, pulmonary, renal or hepatic toxicity from previous treatment;
Prior Autologous or Allogeneic Stem Cell transplantation;
3. Available Healthy Donor without any contraindications for donation. 5/6 or 6/6 related or unrelated donor (molecular typing for DRB1);
4. Patient and/or responsible person able to understand and sign consent
Exclusion Criteria
HIV positive patient
Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater)
Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater)
Child's class C cirrhosis
Unstable cerebral vascular disease or recent hemorrhagic stroke (less than 6 months)
Patients with known allergy to rat serum products
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Methodist Hospital Research Institute
OTHER
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
Baylor College of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
George Carrum
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malcolm K Brenner, MD
Role: STUDY_CHAIR
Baylor College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Texas Children's Hospital
Houston, Texas, United States
The Methodist Hospital
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACHE
Identifier Type: -
Identifier Source: secondary_id
12472
Identifier Type: -
Identifier Source: org_study_id
NCT00602888
Identifier Type: -
Identifier Source: nct_alias